NCT03501069View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants

PHASE1TerminatedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 30, 2018

Primary Completion Date

December 26, 2018

Study Completion Date

December 26, 2018

Conditions
Healthy Volunteers
Interventions
DRUG

TAK-418

TAK-418 capsules.

DRUG

TAK-418 Matching Placebo

TAK-418 matching placebo capsules.

Trial Locations (2)

84124

PRA Health Sciences, Salt Lake City

91206

Parexel International, Glendale

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY